跳至主要内容
临床试验/EUCTR2005-000871-16-GB
EUCTR2005-000871-16-GB进行中(未招募)不适用

Methotrexate in adults with severe atopic dermatitis: a double-blind, randomised, parallel-group, placebo-controlled trial - Methotrexate vs. placebo in adults with severe atopic dermatitis

Dr John Berth-Jones0 个研究点目标入组 48 人开始时间: 2006年2月6日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Diagnosis of AD according to the revised criteria of Hanifin and Rajka (1980)
  • 2. AD of severity assessed as severe, as defined by the criteria of Rajka and Langland (1989)
  • 3. Aged between 16 and 70 years at the screening visit
  • 4. Consistent use of the same topical corticosteroid for at least 1 month prior to the screening visit
  • 5. Whether male or female, acceptance of need to use effective contraception during heterosexual activity, both during the study period and for 3 months after study medication has been discontinued
  • 6. Finding on screening of:
  • - liver enzymes within 10% of the upper limit of normal
  • - normal renal function as assessed by serum creatinine
  • - normal full blood count or minor abnormality not of medical concern
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Known to have liver impairment
  • 2. History of, or currently admit to, high alcohol consumption
  • 3. Known to have renal impairment
  • 4. Suffering from an unexplained haematological abnormality
  • 5. Significant pre-existing immunosuppression from any cause
  • 6. History of malignancy, with the exception of cutaneous basal cell carcinoma
  • 7. Scheduled elective surgical procedure during the trial period
  • 8. Planning to start a family within the trial period or subsequent 3 months, whether male or female
  • 9. In the case of female subjects, are < 8 weeks post partum or breast feeding
  • 10. Suffering from pre-existing pulmonary fibrosis
  • 11. Previous history of intolerance of MTX
  • 12. Use of folate antagonists such as trimethoprim and co-trimoxazole, due to the risk of toxicity
  • 13. Concomitant use of any systemic medication considered by the investigator to be likely to interact with MTX in a clinically significant manner, for example cytotoxic drugs, drugs with clear nephrotoxic or hepatotoxic potential, sulphonamides, pyrimethamine (in some antimalarials), dapsone and phenytoin.
  • 14. Use of the following treatments within the following time limits before study treatment initiation:
  • - systemic corticosteroids during preceding 2 wks
  • - ciclosporin during preceding 2 wks
  • - topical immunosuppressantsduring preceding 4 wks
  • - PUVA / UVB during preceding 4 wks
  • - azathioprine during preceding 8 wks
  • - cytotoxic agents during preceding 8 wks
  • 15. Suffering from active severe systemic infection, including viral hepatitis B or C
  • 16. Likely requirement for vaccination during the course of the study
  • 17. History of past or current substance abuse, psychiatric disease or condition which in the opinion of investigator may invalidate communication with the investigator
  • 18. Any other chronic illness likely to alter the outcome of the study
  • 19. Current participation in another clinical study, or previous participation in one within the preceding 3 months.

研究者

发起方
Dr John Berth-Jones

相似试验